Printer Friendly

Saniona's collaboration partner initiates preclinical development in joint ataxia programme.

M2 EQUITYBITES-August 15, 2017-Saniona's collaboration partner initiates preclinical development in joint ataxia programme

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Biotechnology company Saniona AB (STO:SANION) announced on Monday that Luc Therapeutics, its collaboration partner and a private biotechnology company, has initiated preclinical development for the drug candidate CAD-1883 for ataxia.

The company said Luc Therapeutics has initiated the pre-clinical development with the aim of initiating Phase 1 first man clinical studies in 2018.

Also, Luc Therapeutics will be responsible for further development of compounds identified under the Ataxia programme.

Apart from being a shareholder of Luc Therapeutics, Saniona has rights to royalties on products commercialised by Luc Therapeutics under the Ataxia programme.

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 15, 2017
Words:150
Previous Article:Sweco commissioned for SEK300m project to plan and design modernisation of Stockholm Central Station.
Next Article:Autoliv announces dividend of USD0.60 per share for quarter.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters